Summary
Fidelity Advisor Biotechnology Fund is a mutual fund. It does not trade on an exchange: you buy it from the fund company at a price set once a day. Positions inside: 131. The ten largest make up 51% of the fund.
- Positions
- 131
- Dividend yield
- 1.10%
What speaks for it
- Average yearly growth over the last ten years: 10%.
What to watch
- The ten largest positions make up 51% of the fund, so its result rests on a few names.
- In the last five years its price once dropped by 49% from its high.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- +3.6%
- 3 months
- +2.7%
- This year
- +27%
- 1 year
- +39%
- 3 years
- +106%
- 5 years
- +37%
- 10 years
- +163%
- Avg. market cap
- $132.5B
- P/E
- -
- Forward P/E
- -
- P/S
- 10.5x
- P/B
- 5.6x
- P/FCF
- -
- EV/EBITDA
- -
- Dividend yield
- 0.60%
- ROIC
- -12.6%
- ROE
- -17.1%
- Gross margin
- -742.6%
- Operating margin
- -5,154.3%
- Net margin
- -4,191.9%
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.63
Weighted average of the 50 largest companies, which make up 91% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Concentrated- 1 ABAbbVie ABBV 18%
- 2 GIGilead Sciences GILD 5.3%
- 3 MRModerna MRNA 4.4%
- 4 ALAlnylam Pharmaceuticals ALNY 4.0%
- 5 NTNatera NTRA 3.8%
- 6 INInsmed INSM 3.3%
- 7 SYSpyre Therapeutics, Inc. SYRE 3.2%
- 8 ARArgenx ARGX 3.2%
- 9 RVRevolution Medicines RVMD 3.1%
- 10 AMAmylyx Pharmaceuticals, Inc. AMLX 3.0%
Positions in the fund: 131. The ten largest make up 51% of it.
Composition as of Oct 31, 2026.
Where is it spread?
By company size
- Mega cap 24%
- Large cap 32%
- Mid cap 33%
- Small cap 9.6%
- Micro cap 0.9%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.
Largest size group: Mid cap (33%).
What does it cost me?
We do not know the costs of this fund.
How has it done?
Growing over the long run- A year on average, 10 years
- +10%
- Deepest drop
- -49%
- Yearly volatility
- 25%
Average yearly growth over the last ten years: 10%. Deepest drop in these years: 49% below the earlier high.
Does it pay dividends?
Yes, it pays out- Yield
- 1.10%
- Payments a year
- 1
- Last payment
- $0.57
Over the last 12 months it paid $0.57 per share, which is 1.10% of today's price. The last payment was $0.57 on Dec 26, 2025.
How expensive are the companies inside?
Rather expensive- Average Bulios Score
- 45 out of 100
Weight by Bulios Fair Price
- Undervalued 3.9%
- Fairly valued 18%
- Overvalued 78%
By Fair Price, 78% of the rated weight comes out as overvalued.
Counted from its largest companies (50), which make up 91% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Can I buy it as an ETF?
A mutual fund is bought from the fund company. These ETFs hold much of the same and trade on an exchange, so an ordinary broker carries them.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
TD TDNA T. Rowe Price Biotech ETF | United States | 0.55% | $9.96M | - | - | 39% |
FM FMED Fidelity Disruptive Medicine ETF | United States | 0.50% | $74.1M | +23% | Pays out | 38% |
IB IBB iShares Biotechnology ETF | United States | 0.44% | $11.5B | +38% | Pays out | 37% |
CU CURE.AX Global X - S&P Biotech ETF | Australia | 0.45% | $28.3M | +30% | Reinvests | 34% |
XB XBI SPDR S&P Biotech ETF | United States | 0.35% | $8.16B | +43% | Pays out | 34% |
2B 2B70.DE iShares Nasdaq US Biotechnology UCITS ETF | Ireland | 0.35% | $973.7M | +42% | Reinvests | 32% |
